Figure 4 - Management of asthma patients during COVID-19
pandemic
Assuring patients safety can be provided by prevention of infection with
SARS-CoV2 and appropriate control of asthma. In addition to personal
protection by using a mask, hand sanitizer, washing hands and socially
distancing, the control of asthma symptoms is essential. The decision of
sustaining or postponing the therapy of asthma (severe) patients must be
taken multidisciplinary and based on individual circumstances. The usage
of ICS and other asthma controllers should be continued. Several EAACI
position papers have been published on patient management during the
COVID-19 pandemics that should be referred in specific conditions, such
as biological usage, allergen immunotherapy, drug hypersensitivity,
venom immunotherapy, ophtalmology and asthma. EAACI, European Academy of
Allergy and Clinical Immunology; COVID, Coronavirus Disease 2019; Inhale
corticosteroids, ICS.